D eficient thymopoiesis is currently considered to be one of the most important determinants of impaired immune competence in the later time period after allogeneic hematopoietic stem cell transplantation (HSCT) (1) (2) (3) . Although T cell recovery after allogeneic HSCT may occur through thymus-independent peripheral expansion of mature T cells infused with the graft, thymopoiesis is considered pivotal for generating a diverse TCR repertoire (4, 5) . Thymopoiesis may be compromised by chemo-or radiotherapy-induced epithelial injury, ageassociated thymic involution, and especially by graft-versus-host disease (6) (7) (8) (9) (10) (11) . We recently showed that failure to recover thymopoiesis significantly predicts for subsequent severe infections and mortality, independent from other earlier established risk factors (E.-J. Wils, B. van der Holt, A.E.C. Broers, S.J. Posthumus-van sluijs, J.W. Gratema, E. Braakman, and J.J. Cornelissen, submitted for publication). Therefore, strategies to improve posttransplant immune competence should be focused on the restoration of thymopoiesis (1, (12) (13) (14) . Approaches to boost thymopoiesis that are currently being explored either target T cell progenitors directly [FLT3 ligand (FLT3L) (15, 16) and or the nursing thymic stromal compartment (keratinocyte growth factor, sex steroid ablation, and growth hormone/insulin-like growth factor-1) (13) .
Another possible thymopoietic agent is stem cell factor (SCF). SCF is a cytokine produced by stromal cells including thymic stroma, and its receptor, c-Kit, is expressed by the earliest thymocytes. SCF-c-Kit signaling has been shown to be essentially involved in early thymocyte differentiation into the T cell lineage and thymic niche availability (17) (18) (19) (20) (21) (22) . SCF may experimentally accelerate peripheral leukocyte recovery following high-dose radiotherapy (23) and was recently shown to improve murine thymopoiesis when combined with IL-7 (24) . However, it remains unclear whether exogenous supply of SCF alone may affect thymopoiesis and peripheral T cell recovery following experimental murine and human stem cell transplantation. In the current study, we evaluated whether SCF would improve recovery of thymopoiesis following murine bone marrow transplantation (BMT) and also following human stem cell transplantation in mice humanized for components of the immune system (human immune system [HIS] mice). Our results demonstrate that exogenous-supplied SCF significantly enhances thymopoiesis both after murine BMT and human fetal liver (FL) HSCT in mice by a direct thymopoietic effect.
Materials and Methods

Mice
RAG-2
2/2 common cytokine g-chain (IL-2Rgc) 2/2 mice on a mixed background (originally bred at The Netherlands Cancer Institute, Amsterdam, The Netherlands) were inbred on a BALB/c background. RAG-1 2/2 (CD45.2 on C57BL/6 background) and C57BL/6 (CD45.1) mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Mice were bred under specific pathogen-free conditions at the Erasmus Medical Center Experimental Animal Center or in individual ventilated cages in the Animal Biosafety Level 2 animal facility of the Academic Medical Center of the University of Amsterdam (Amsterdam, The Netherlands). Food and water were available ad libitum. Housing, care, and all animal experiments were performed in accordance with Dutch legal regulations, which include approval by an ethical committee.
Transplantation of murine bone marrow and human FL cells
Bone marrow cells (BMC) obtained from crushed femurs and tibias of donor mice were depleted of T cells by incubation with rat anti-mouse CD4 (YTS191, YTA312) and rat anti-mouse CD8 (YTS169) mAbs for 30 min on ice, followed by a wash and immunomagnetic depletion using goat anti-rat IgG microbeads and the autoMACS (Miltenyi Biotec, Bergisch Gladbach, Germany). The efficacy of T cell depletion was estimated prior to transplantation for each experiment and estimated at .2 log (2 to 3 logs). Tento 12-wk-old RAG-1 2/2 mice were 3 Gy irradiated ([ 137 Cs] g-source, Gammacell; Atomic Energy of Canada, Ottawa, Ontario, Canada) and received 2 3 10 5 T cell-depleted C57BL/6 (CD45.1) congeneic BMC by tail vein infusion.
The HIS mice model was generated as described previously (25, 26) . In short, newborn (days 3-7) RAG-2 
CD38
low using an FACSAria (BD Biosciences) to purity always $95%.
Cytokine administration
Recombinant rat (rr) and recombinant human (rh) SCF were kindly provided by Amgen (Thousand Oaks, CA). Recipient mice of murine BMC received PBS or rrSCF (100 mg/kg/injection) by s.c. injection three times a week from day 1 until the end of the experiment. In HIS mice, PBS or rhSCF (100 mg/kg/injection) was administered i.p. three times weekly as of day 14 following transplantation.
Flow cytometric analysis
At different time points following murine HSCT and human into mouse HSCT, bone marrow (BM), liver, thymus, peripheral blood, lymph node (LN), or spleen was harvested and analyzed using flow cytometry. Murine BMT model. Absolute numbers of subsets of peripheral blood leukocytes were determined by single-platform flow cytometry as described previously. mAbs against murine epitopes used for flow cytometric analysis were: anti-CD3, anti-CD4, anti-CD8, anti-Dx5, anti-CD19, anti-CD45.1, and anti-Gr-1 (BD Pharmingen, San Jose, CA). Thymic and BM subsets were defined and analyzed as previously described (16 (27, 28) . In brief, BMC were stained with a mixture of biotin-conjugated lineage panel (NK1.1-bio, MAC-1-bio, Gr1-bio, TER-119-bio, CD3e-bio, and CD19-bio). Subsequently, cells were washed, and Lin + cells were visualized by streptavidin-conjugated Pacific Orange. Subsequently, cells were also stained using Alexa 700-conjugated anti-sca-1, allophycocyanin-H7-conjugated anti-c-Kit, PE-conjugated anti-flt3, PeCy7-conjugated anti-CD127, PerCP-Cy5.5 anti-CD93, CD34-Alexa 647, efluor 450-anti-B220, and FITC-conjugated anti-CD45.1. HIS model. Peripheral blood and lymphoid organs were harvested and analyzed at different time points following transplantation. Mice were excluded from further analysis when BM human chimerism was ,2.5%. To obtain a single-cell suspension, organs were minced and passed through a nylon mesh. Only the liver-cell suspensions were ficolled, and mononuclear cells were isolated. Cells were washed and counted using a Casy counter (Roche Diagnostics, Almere, The Netherlands). Absolute numbers of cell subsets in organs were determined by multiplying the number of nucleated cells by the percentage of positive cells for the indicated cellsurface marker(s). mAbs against human epitopes used for flow cytometric analysis were CD45 (2D1), CD33, CD34 (8G12), CD38 (HB7), c-Kit (CD117), CD3 (SK7), CD4 (SK3), CD8 (SK7), CD14 (M5E2), CD19 (HIB19), HLA-DR (BD Biosciences), blood dendritic cell Ag 2 (BDCA2) (AC144; Miltenyi Biotec), and CD1a (T6-RD1; Beckman Coulter 
Statistical analysis
Statistical comparisons of experimental data between recipients of PBS or SCF groups were performed with a two-sided Mann-Whitney U test for unpaired data. The p values .0.05 were considered significant. Recovery data of groups of mice are presented as box-whisker plots, showing median, 25-75th percentiles (box), 10-90th percentiles (whiskers), and outliers (asterisks).
Results
SCF improves thymopoiesis and T cell recovery after murine HSCT
We first evaluated whether SCF administration would affect thymic recovery following murine T cell-depleted (CD45.1) BMT in congeneic RAG-1 2/2 (CD45.2) mice. Mice were treated three times weekly with PBS or rrSCF s.c. as of day 1 until 4 or 6 wk posttransplantation. Thymic cellularity and thymocyte subsets of donor origin were determined in thymi of SCF-(n = 5) and PBStreated (n = 5) BMT mice at 4 wk posttransplantation. As depicted in Fig. 1A , median numbers of total donor-derived thymocytes measured 9 3 10 3 in PBS-treated mice and 2660 3 10 3 in SCFtreated animals (p = 0.05). Although all thymocyte subsets increased following SCF, significant increases were observed in the DP, CD4 SP, and CD8 SP thymocyte subsets. In PBS-treated mice, the median number of DP, CD4 SP, and CD8 SP thymocytes measured 0.5, 0, and 0 3 10 3 per thymus, respectively. Mean numbers and ranges of the DN, DP, and SP subsets estimated, , respectively. The recovery of the DP and SP thymocyte subsets appeared enhanced in SCF-treated mice with median numbers of DP, CD4 SP, and CD8 SP thymocytes estimated at 2400, 66, and 31 3 10 3 per thymus, respectively ( , respectively. Next, we assessed whether SCF-induced improved thymopoiesis would translate into improved peripheral T cell recovery. Absolute numbers of donor-derived newly developed CD4 + and CD8 + T cells were very low in mice treated with PBS or SCF until 4 wk after transplantation in spleen and LN (Table I) . Therefore, evaluation of peripheral T cell recovery was also performed in mice treated for 6 wk. T cell numbers increased + T cell recovery. Peripheral blood T cell recovery at that time point showed a nonsignificant trend toward improved T cell recovery. Of note, donor B cell, NK cell, dendritic cells, and myeloid recovery as measured in peripheral blood, spleen, and LN were similar between PBS-and SCF-treated mice (data not shown). Furthermore, SCF administration did not affect overall donor chimerism (Supplemental Fig. 1) .
As c-Kit is expressed on hematopoietic progenitor cells in BM, including myeloid precursor cells and progenitors with lymphoid and thymic-seeding potential, SCF may exert its beneficial effect directly by improving thymocyte proliferation and differentiation or alternatively by expansion of lymphoid progenitors at the BM level. Therefore, we addressed the question whether SCF would expand prethymic BM progenitors, including LT-HSC, ST-HSC, MPP, ELP, EPLM, CLP1, and CLP2. These subsets were quantified in PBS-and SCF-treated BMT mice after 4 wk of treatment (Table II) Collectively, these results suggested that SCF improves thymopoiesis by a direct effect at the thymus level rather than by enhanced entry of lymphoid progenitors, as we earlier observed in mice treated by FLT3L following murine BMT (16) . To address the question of whether our results with SCF might be translated to a human setting, we next studied the effect of SCF in our recently developed HIS mouse model, as this humanized model may closely resemble human thymopoiesis (25) . ), and peripheral blood (per microliter of blood) of mice receiving a congenic BMT and were treated with PBS (n = 4) or SCF (n = 5) for 4 or 6 wk (PBS, n = 8, versus SCF, n = 10).
*p , 0.05 comparing PBS versus SCF. ND, not determined.
SCF improves human thymopoiesis in HIS mice
The 3.5 Gy-irradiated newborn RAG-2 2/2 IL-2Rgc 2/2 mice were transplanted intrahepatically with 5-10 3 10 4 CD34 + CD38 low -selected human FL cells and treated with rhSCF or PBS three times weekly i.p. as of week 2 for 2, 4, or 6 wk. Thymic cellularity and human thymocyte subsets were quantified in thymi of SCFand PBS-treated HIS mice at 4, 6, and 8 wk after transplantation as outlined in the Materials and Methods section (Fig. 2B) . Overall, human thymic cellularity was significantly increased in SCF-treated mice at both 6 and 8 wk posttransplantation (Fig. 3) . Median thymic cellularity measured 176 and 326 3 10 3 /thymus at 6 wk (p = 0.04) and 123 and 585 3 10 3 /thymus at 8 wk posttransplantation (p = 0.01) in PBS-and SCF-treated HIS mice, respectively. Although DN and early DP thymocyte recovery were not significantly enhanced in SCF-treated HIS mice (Fig. 4A, 4B) , late DP, CD4 SP, and CD8 SP thymocyte subsets were significantly increased in thymi of SCF-treated as compared with PBStreated HIS mice (Fig. 4C-E 
Peripheral T cell recovery in HIS mice
We recently observed impaired peripheral human T cell survival in the HIS model (26) , thereby allowing us to study peripheral recovery only to a limited extent. Therefore, we also evaluated whether the observed enhancement of thymopoiesis would result in better T cell recovery in peripheral organs. Absolute numbers of T cells, but also B cells, pDCs, and monocytes were determined in spleen and liver of HIS mice at weeks 4 and 8. Results are shown in Table III . In PBS-treated HIS mice, human leukocyte recovery in spleen and liver increased from week 4 to week 8. Median splenic B cell numbers measured 8. 
SCF transiently improves human progenitor cell recovery
Given the observed improved B cell recovery, the improved thymopoiesis, and the well-known expression of c-Kit on human hematopoietic progenitor cells, we evaluated whether administration of SCF would affect engraftment and recovery of human progenitors in BM and liver of HIS mice. Results are depicted in 
Discussion
Deficient thymopoiesis is currently considered the most important determinant of impaired immune competence in human recipients of allogeneic stem cell grafts in the later time period after transplantation (1, 3) . Although severely compromised in older transplant recipients, the thymus still retains the ability to support T cell development, even in patients .40 y of age (29, 30) . However, recapitulation of thymopoiesis may take many months if not years, which may confer a substantial risk for opportunistic infections and death in older transplant recipients (11, 31, 32) . Therefore, new approaches to restore or boost thymopoiesis are currently receiving considerable attention, including the application of cytokines that are critically involved in thymopoiesis. We and others experimentally explored the cytokines IL-7 (33-37) and FLT3L (15, 16) , and these studies fueled their potential for further clinical development. Although IL-7 and FLT3L have been studied more elaborately, the early acting hematopoietic cytokine SCF has so far received relatively little attention (24) . Apart from its role in the earliest phases of hematopoiesis, SCF is also critically involved in thymopoiesis with expression of its receptor on developing thymocytes before the expression of the Ag-specific TCR (17, 18) . It provided the rationale to study SCF in a murine BMT model as well as in humanized mice as a preferable translational model.
In the current study, we demonstrate that exogenous administration of SCF significantly improves thymopoiesis in both mod- els. Only limited expansion of hematopoietic precursors at the BM level was observed, suggesting that SCF may boost thymopoiesis by directly stimulating T cell development within the murine thymus.
Murine hematopoiesis and lymphopoiesis originates from selfrenewing, multipotent, c-Kit + LT-HSCs that develop via ST-HSC and MPP into progenitor cells with lymphoid potential. LSK cells and the MPP (LSKflt3 + ) subset may develop into CLP1 and CLP2 that predominantly give rise to B cells and show low c-Kit expression (38) . Of note, only the lymphoid-primed MPP and CLP subsets have been shown to efficiently seed the murine thymus (39) (40) (41) . Intrathymically, c-Kit + early thymic progenitors develop via DN2 into DN3 and lose c-Kit expression (17) . TCR-positive thymocytes that mature into CD4SP or CD8SP thymocytes lack c-Kit expression, which remains so after egress from the thymus and during the development of the peripheral immune response. In the current study, exogenous SCF significantly enhanced murine thymopoiesis after T cell-depleted BMT with most pronounced expansion of TCR-positive thymocytes. The DN subset was only marginally affected, suggesting that c-Kit + thymocytes rapidly complete their rearrangement and express the TCR upon SCF stimulation, followed by strong expansion of the DP subset. In line with the earlier observed impaired thymopoiesis in c-kit subsets (LT-HSC) was observed in the BM of SCF-treated mice, but the lymphoid-biased c-Kit + subsets, including (lymphoid-primed) MPP and CLP with thymic seeding potential, were not affected by SCF administration. Previously, we and others showed that exogenous administration of FLT3L did expand MPP and CLP, which preceded an increase of thymocytes and enhanced thymopoiesis (16, 43) . That observation and the absence of SCFmediated expansion of BM progenitors with thymic seeding potential suggest that it is unlikely that enhanced thymic seeding has accounted for improved thymopoiesis in our murine model.
Murine models may mirror human hematopoiesis remarkably well, but important differences remain that hamper the proper translation of murine findings into potential human applications (44) . To bridge the translational gap, HIS mice have been developed that allow the study of the human immune physiology. In addition, the HIS model allows for a more rapid and cost-effective evaluation of promising candidates to manipulate human hematopoiesis and lymphopoiesis, as in the current study. Of note, human T cell lymphopoiesis differs considerably from murine lymphopoiesis. Human HSC are enriched in Lin 2 CD34 + CD38 2 CD90 + BMC and develop via CD90 2 MPP (45) into more differ- 2 ) in spleen and liver at 4 and 8 wk posttransplantation in HIS mice treated with PBS (n = 8 and 10) or SCF (n = 10 and 13).
*p , 0.05 comparing PBS versus SCF.
entiated CD34 + CD38 + progenitors. CD33 upregulation is associated with a bias toward myeloerythroid potential (46) , and CD10 or CD7 expression is associated with lymphoid and thymic seeding potential (47) (48) (49) (50) . Human thymocytes develop into mature human T cells via a highly ordered process within the human thymus (49) . Similar to murine thymocytes, c-Kit is expressed on the earliest human DN thymocytes (18, 51, 52) . In contrast, c-Kit is more abundantly expressed on primitive murine hematopoietic progenitor cells, whereas human c-Kit is preferentially expressed on myeloid and also lymphoid-committed progenitors (48, 53) . These differences of expression by hematopoietic progenitors may at least in part explain the SCF-mediated expansion of LT-HSC after murine BMT, whereas such an effect was absent in the HIS model. In line with previous in vitro studies (54, 55) hi CD33 2 c-Kit + subset accounts for the observed improvement of thymopoiesis. First, the increase of B cell recovery appeared relatively modest and was only observed at week 4, whereas B cells are the preferred leukocyte subset that rapidly develops following engraftment in HIS mice. Second, other lymphoid cells like NK cells, and pDCs were not enhanced in SCF-treated HIS mice, arguing against an effect on a CLP. Third, in contrast to the effect of FLT3L in our murine model (16) , SCF selectively enhanced T cell recovery, whereas other lymphoid subsets were not affected. In addition, SCF did not enhance murine lymphoid progenitor cell recovery (i.e., ST-HSC, MPP, and CLP1), contrasting the effect of FLT3L on these lymphoid progenitors. On the contrary, previously described CD7 + or CD10 + lymphoid-biased progenitors (48, 50) express c-Kit, are present in the CD34 + CD38 hi CD33 2 c-Kit + subset, and are the most likely prethymic progenitors that seed the human thymus. In vitro, CD7 + lymphoid progenitors especially seeded thymic tissue upon SCF treatment (combined with IL-7 and IL-2) (48), possibly suggesting that SCF may also be implicated in thymic entry in our model. Improved thymopoiesis following murine BMT preceded an increase in T cell numbers in lymphoid organs following SCF administration in mice, suggesting that egress of newly developed T cells predominantly caused an improved peripheral T cell recovery, although we cannot exclude that peripheral expansion may have contributed to some extent. Despite a similar increase in thymic recovery, T cell numbers were not increased in SCF-treated HIS mice. HIS mice recapitulate the development of hematolymphoid development, but homeostatic support of mature T cells in peripheral organs has remained rather poor. HIS mice remain a hybrid human-mouse system in which cytokine receptor compatibility between species and MHC-HLA mismatch may compromise mature T cell survival (56, 57) . As SCF selectively affects T cell progenitor cells, in contrast to IL-7 (26, 58) and IL-15 (59) , improved survival of mature T cells following rhSCF was not expected. However, further study of functional immune competence in humanized mice would require optimized peripheral T cell homeostasis and survival (60) . Despite the abundant presence of human APCs (B cells, monocytes), the survival and expansion of newly developed human T cells needs to be improved. We recently showed no significant effect of IL-7 on peripheral T cell numbers in HIS mice (26) , possibly suggesting that more complete human donor chimerism should be pursued, instead of a persisting and even declining situation of mixed and split chimerism of the various hematopoietic lineages. Nevertheless, HIS mice do allow for studying possible thymopoiesis-stimulating agents in a translational perspective. Apart from human FLderived HSC, also clinically used stem cell sources such as umbilical cord blood may be used to further bridge a translational gap.
In summary, exogenous SCF significantly enhanced both murine and human thymopoiesis in translational models of severe lymphopenia, as can be observed clinically following HSCT. These results justify further preclinical and toxicology studies aimed at the potential application of SCF after human HSCT for improving thymopoiesis. Table S1 Median percentages of donor-chimerism (range) within indicated cell population in PBS-versus SCFtreated mice at 4 weeks post-transplantation. PB peripheral blood; DN: double negative thymocytes. * p<0.05 using Mann-Whitney U-test.
